MIVI Neuroscience, Inc.

12 articles about MIVI Neuroscience, Inc.

• MIVI Neuroscience™ Presents Primary Endpoint Results from the EvaQ Trial — at the 2024 International Stroke Conference

  2/8/2024

  MIVI Neuroscience, Inc. (Eden Prairie, MN) announces the primary endpoint results of its EvaQ Trial, a prospective, multi-center, global, single arm, FDA-regulated IDE trial study to evaluate the safety and effectiveness of the MIVI Q™ Revascularization System for treating acute ischemic stroke.

• 

  Money on the Move: January 21-26

  1/27/2021

  A brief rundown of who’s raking in cash in the biopharma world.

• MIVI Neuroscience Secures Series B Funding - Jan 21, 2021

  1/21/2021

  MIVI Neuroscience, a medical device company focused on improving clinical outcomes for ischemic stroke patients, announced the closing of its Series B funding including $35 million in new money plus the conversion of previously issued convertible notes.

• MIVI Neuroscience Announces First Patient Enrolled in EVAQ Clinical Study for Ischemic Stroke Treatment

  12/1/2020

  MIVI Neuroscience, Inc. announced that it has enrolled the first patient in the Food and Drug Administration approved Investigational Device Exemption EVAQ Clinical Study.

• MIVI Neuroscience Announces FDA IDE Clinical Study Approval For the MIVI Q Aspiration Catheter

  6/9/2020

  MIVI Neuroscience, a leading developer, and marketer of precision stroke therapy devices utilized by neurointerventionists around the world, announced today that the FDA has determined the company has provided sufficient data to support initiation of a human clinical study of the MIVI Q Aspiration Catheter in the United States.  T

• MIVI Neuroscience Promotes Bob Colloton to CEO and Appoints Robert Stern to Board of Directors

  3/30/2020

  MIVI Neuroscience announced that Bob Colloton has been promoted to the role of Chief Executive Officer effective March 30, 2020, following the resignation of MIVI's current CEO, Jim McCollum.

• Fred Moll Named Chairman of the Board at MIVI Neuroscience

  10/10/2019

  Dr. Moll has founded or co-founded multiple innovative medical device companies, and has served on numerous boards throughout his career.

• MIVI Neuroscience Appoints Fred Moll, M.D. to Its Board of Directors

  9/10/2018

  MIVI Neuroscience, Inc. announced today the appointment of Fred Moll, M.D. to its Board of Directors.

• MIVI Neuroscience Expands European Commercialization Network After Achieving CE Mark Approval Of The R4Q Revascularization Catheter For Ischemic Stroke

  7/1/2018

  MIVI Neuroscience, Inc. announced the expansion of its European commercialization network with the commitment from AngioNautix of Madrid, Spain, to be its partner in Spain, Portugal and Cuba.

• MIVI Neuroscience Announces First-In-Man Series of The DAISe Clot Management System

  6/29/2018

  MIVI Neuroscience, Inc. announced it has successfully achieved first-in-man usage of the DAISe Clot Management System for next generation treatment of ischemic stroke.

• MIVI Neuroscience Begins European Commercialization After Achieving CE Mark Approval Of The R4Q Revascularization Catheter For Ischemic Stroke

  3/29/2018

  MIVI Neuroscience, Inc. announced it has received CE Mark approval for the R4Q Revascularization Catheter for the removal of fresh, soft emboli and thrombi in the peripheral and neurovascular systems.

• MIVI Neuroscience Selects Bob Colloton to Lead Worldwide Commercialization Of Innovative Treatment Solution for Ischemic Stroke

  1/23/2018

  Bob brings 27 years of proven experience in medical device sales and market development and branding expertise, with a deep understanding of the neurovascular market in particular.